The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | AML & Myelodysplasia breakthrough
For a time there had been very few new treatments for acute myeloid leukemia (AML) and Myelodysplasia, and recently there has been an ‘avalanche’ of new treatments for these diseases. Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, tells us about the extremely positive responses seen in the use of a new monoclonal antibody in combination with azacitidine. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
